Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors K J Harrington J Brody M Ingham J Strauss S Cemerski M Wang A Tse A Khilnani A Marabelle T Golan
Title Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
Journal Vol Issue Date Pages Journal Short Title
Ann Oncol
URL https://academic.oup.com/annonc/article/29/suppl_8/mdy424.015/5141570
Abstract Text Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Ulevostinag Ulevostinag 0 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
Ulevostinag MK 1454|MK-1454 STING1 Agonist 19 Ulevostinag (MK-1454) is an agonist of the stimulator of interferon genes protein (TMEM173, STING1), that when activated leads to the release of cytokines that stimulate cytotoxic T lymphocytes to enhance the anti-tumor immune response (Ann Oncol, Oct 2018, 29 (suppl 8), abstract LBA15, PMID: 31355488).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References